Clinical Trials Logo

Salivary Gland Neoplasms clinical trials

View clinical trials related to Salivary Gland Neoplasms.

Filter by:

NCT ID: NCT06145308 Recruiting - Precision Therapy Clinical Trials

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate, etc.) and safety of precision neoadjuvant or conversion therapy.

NCT ID: NCT06091878 Not yet recruiting - Clinical trials for Salivary Gland Cancer

Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers

INDAGA-UK
Start date: March 1, 2024
Phase:
Study type: Observational

The INDAGA-UK trial is a retrospective, multi-centre observational study in participants with locally advanced and recurrent salivary gland to investigate t its molecular profiling, and to explore new prognostic and druggable markers. We will analyse samples and data from patients diagnosed with salivary gland cancer from 2013 - 2023. Subject and sample identification will occur over a 12-month period. Samples and data will be analysed over the next 12 months prior to study end.

NCT ID: NCT06047236 Recruiting - Clinical trials for Salivary Gland Tumor

Immune Biomarker Study for Salivary Gland Carcinoma

ImmoGlandula
Start date: January 8, 2024
Phase:
Study type: Observational

Aims of this study are analyses of tumor metabolome, tumor transcriptome and tumor proteome as well as of the immune infiltration, separated by histological entity. These data will subsequently be compared with the with the detailed immune status determined in the patient's peripheral blood and saliva using machine learning techniques, among others, to create a biomarker cluster for salivary gland tumors. These can be used in clinical routine. In addition, the investigators would like to study a subset of patients from freshly resected tumor organoids from freshly resected tumor tissue according to already established methods in order to mechanistic investigations of prognostic parameters.

NCT ID: NCT06034782 Completed - Diagnosis Clinical Trials

Diagnostic Accuracy of Fine Needle Aspiration in Patients With Salivary Gland Tumors.

Start date: February 22, 2021
Phase:
Study type: Observational [Patient Registry]

Tumors of the salivary glands occupy 0.5-1.2% of cases of head and neck tumors. They are primarily a surgical disease, as their treatment is basically the surgical excision. In this direction and in the context of the differential preoperative diagnosis, in addition to the imaging methods, the fine needle biopsy (FNA) was used, with which cell material is aspirated from the tumor and studied under the microscope. Although an increasing number of papers have been published in the international scientific literature over the last 5 years on the diagnostic accuracy of FNA in salivary glands, many of them are unable to quantify and omit to refer information that could affect the estimated diagnostic accuracy. Such information is for instance the clinical experience of the doctor who performs the FNA and of the one who assess the smear. The aim of this retrospective study is to evaluate the diagnostic accuracy of fine needle biopsy in adult patients with salivary gland tumor that underwent a surgical excision in two Oral and Maxillofacial Departments in Northern Greece. The present retrospective study was carried out from 2/2021 to 4/2022 by collecting data from the files of patients who underwent surgery at the Oral and Maxillofacial Clinic of the Theageneio Cancer Hospital of Thessaloniki 1996-2022 and the General Hospital of Thessaloniki G. Papanikolaou 2015-2022. The study was conducted according to the STARD 2015 protocol. FNA contributed significantly to the differential preoperative process in salivary gland diseases. The differential diagnosis of a lesion in benign / malignant preoperatively, with the use of FNA, enables the surgeon for a more beneficial to the patient and oncologically safer planning of the surgery. It is considered important the high sensitivity provided by the examination, as it helps to exclude with sufficient safety the possible malignancy of the tumor located in the salivary gland of the patient.

NCT ID: NCT05924256 Recruiting - Clinical trials for Advanced Salivary Gland Carcinoma

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Start date: July 26, 2023
Phase: Phase 2
Study type: Interventional

This is a single-center, open-label, phase 2 study to evaluate the efficacy and safety of target therapy for patients with relapsed/metastastic salivary gland carcinoma based on molecular typing.

NCT ID: NCT05898373 Not yet recruiting - Clinical trials for Salivary Gland Cancer

Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Start date: June 7, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

(1) To apply Bayesian statistics to screen for the most effective treatment regimen containing recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) for locally advanced or metastatic salivary gland ductal carcinoma expressing HER2 in the near future. (2) To explore biomarkers relevant to the efficacy of recombinant humanized anti-HER2 monoclonal antibody-MMAE-coupled vedicitumomab (Edisil, RC48) in the treatment of HER2-expressing locally advanced or metastatic salivary gland ductal carcinoma.

NCT ID: NCT05884320 Recruiting - Clinical trials for Salivary Gland Cancers

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Start date: July 27, 2023
Phase: Phase 2
Study type: Interventional

To learn if sacituzumab govitecan can help to control salivary gland cancer.

NCT ID: NCT05786716 Recruiting - Solid Tumor Clinical Trials

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

DETERMINE
Start date: March 7, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved as standard of care treatment for adult patients with metastatic breast cancer. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Trastuzumab and pertuzumab work in patients with these types of cancers which have a molecular alteration called HER2 amplification or HER2 activating mutation. Investigators now wish to find out if it will be useful in treating patients with other cancer types which are also HER2 amplified or HER2 mutated. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future. This trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.

NCT ID: NCT05727410 Recruiting - Clinical trials for High-grade Salivary Gland Carcinoma

Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma

Start date: November 15, 2022
Phase: Phase 2
Study type: Interventional

1. Primary Objective: - Major pathologic response rate defined by ≤ 10% of tumor composed of viable tumor 2. Secondary Objectives: - Complete resection rate - Response rate to neoadjuvant therapy according to RECIST 1.1 - Downstaging at pathologic staging compared to clinical staging performed at study entry - Distant metastasis free survival (DMFS) rate at 2 years - Disease free survival at 2 years - Overall survival rate at 2 years - Safety and feasibility 3. Exploratory Objectives: - PD L1 expression by 28-8 immunohistochemistry - IHC (HER2, AR, etc) - Whole exome sequencing (WES) - Whole transcriptome sequencing (WTS) - Peripheral blood biomarkers (CD4+ T cells, CD8+ T cell, myeloid derived suppressor cells (MDSC), Treg etc) - Interferon gamma related gene expression profile - Multiplex florescence measure of tumor cells and tumor microenvironment cells

NCT ID: NCT05694819 Active, not recruiting - Clinical trials for Salivary Gland Cancer

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Start date: April 17, 2020
Phase: Phase 2
Study type: Interventional

This study is an open-label phase 2 study to evaluate the safety and efficacy of Darolutamide monotherapy in patients with androgen receptor-positive salivary gland carcinoma. Moreover, this study will evaluate the safety and efficacy of Darolutamide and Goserelin combination in patients with androgen receptor-positive salivary gland carcinoma.